Ascletis Pharma (HKG:1672) said ASC47 the results for its new weight-loss drug, in combination with semaglutide, according to a Wednesday filing with the Hong Kong bourse.

In preclinical trials, the combination led to a 36.2% reduction in body weight in obese mice, outperforming semaglutide alone with muscle mass preserved.

The company plans further studies, with Phase II A results expected in 2025, aiming to advance obesity treatment options.

The pharmaceuticals shares were down by over 13% at day end.